Benzodiazepine use in Sao Paulo, Brazil

Authors

  • Angela Maria Campanha Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, I Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0003-1845-8311
  • Beatriz Ravagnani Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0002-6077-9461
  • Igor André Milhoranc¸a Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0003-3649-0358
  • Márcio Antonini Bernik Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Programa de Ansiedade https://orcid.org/0000-0001-7922-6747
  • Maria Carmen Viana Universidade Federal do Espirito Santo, Centro de Estudos e Pesquisa em Epidemiologia Psiquiatrica, Programa de Pos-Graduacao em Saude Coletiva, Departamento de Medicina Social https://orcid.org/0000-0002-0464-4845
  • Yuan-Pang Wang Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0001-7076-8312
  • Laura Helena Andrade Universidade de Sao Paulo, Faculdade de Medicina, Departamento e Instituto de Psiquiatria, Nucleo de Epidemiologia Psiquiatrica (LIM-23) https://orcid.org/0000-0002-2362-3521

DOI:

https://doi.org/10.6061/clinics/2020/e1610

Keywords:

Psychiatry, Pharmacy, Psychotropic Drugs, Hypnotics and Sedatives, Benzodiazepines

Abstract

OBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of Sa˜o Paulo, Brazil. METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition. RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged X50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use. CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required.

Downloads

Downloads

Published

2020-07-27

Issue

Section

Original Articles

How to Cite

Campanha, A. M., Ravagnani, B., Milhoranc¸a, I. A., Bernik, M. A., Viana, M. C., Wang, Y.-P., & Andrade, L. H. (2020). Benzodiazepine use in Sao Paulo, Brazil. Clinics, 75, e1610. https://doi.org/10.6061/clinics/2020/e1610